TSE:TRL

Trilogy International Partners Stock Forecast, Price & News

C$1.97

+0.01 (+0.51 %)

(As of 06/14/2021 02:59 PM ET)

Add

Compare

Today's Range

C$1.96

▼

C$2.00

50-Day Range

C$1.59

▼

C$2.00

52-Week Range

C$0.85

▼

C$2.11

Volume38,746 shs

Average Volume35,047 shs

Market CapitalizationC$118.04 million

P/E RatioN/A

Dividend Yield1.43%

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive TRL News and Ratings via Email

Sign-up to receive the latest news and ratings for Trilogy International Partners and its competitors with MarketBeat's FREE daily newsletter.

About Trilogy International Partners

TIP Inc. is the parent of Trilogy International Partners LLC ("Trilogy LLC"), an international wireless and fixed broadband telecommunications operator formed by wireless industry veterans John Stanton, Theresa Gillespie and Brad Horwitz. Trilogy LLC's founders have successfully bought, built, launched and operated communications businesses in 15 international markets and the United States. Trilogy LLC, together with its consolidated subsidiaries in New Zealand (Two Degrees Mobile Limited, referred to below as "2degrees") and Bolivia (Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A., referred to below as "NuevaTel"), is a provider of wireless voice and data communications services including local, international long distance and roaming services, for both subscribers and international visitors roaming on its networks. Trilogy LLC also provides fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia.

Trilogy International Partners (TSE:TRL) Hits New 52-Week High at $2.00
June 14, 2021 | americanbankingnews.com

Trilogy International Partners Inc. Announces Expiration and Final Results of the Exchange Offer and Consent Solicitations to Extend Debt Maturity to May 2023
June 4, 2021 | finance.yahoo.com

Trilogy International Partners (TSE:TRL) Reaches New 52-Week High at $2.00
June 2, 2021 | americanbankingnews.com

Trilogy International Partners Inc. (TSE:TRL) Director Brad Horwitz Purchases 200,000 Shares
May 31, 2021 | americanbankingnews.com

Insider Buying: Trilogy International Partners Inc. (TSE:TRL) Director Acquires 119,900 Shares of Stock
May 25, 2021 | americanbankingnews.com

Trilogy International Partners Inc. Announces Receipt of Consents Required to Extend the Maturity of its Debt to May 2023
May 21, 2021 | finance.yahoo.com

Trilogy International Partners (TSE:TRL) Hits New 1-Year High at $1.90
May 20, 2021 | americanbankingnews.com

New Zealand's 2degrees mulls listing in Australia, New Zealand
March 24, 2021 | nasdaq.com

Steven Spurrier, Who Upended Wine World With a Tasting, Dies at 79
March 16, 2021 | nytimes.com

News for Trilogy International Partners Inc Registered Shs
December 24, 2020 | markets.businessinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:TRL
Previous SymbolTSE:AQX.A
CUSIPN/A
CIKN/A
Webwww.trilogy-international.co...
Phone+1-425-4585900
Employees1,663
Year FoundedN/A

Sales & Book Value

Annual SalesC$626.85 million
Price / Sales0.19
Cash FlowC$1.19 per share
Price / Cash Flow1.66
Book ValueC($1.60) per share
Price / Book-1.24

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares59,921,000
Market CapC$118.04 million
Next Earnings Date6/14/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.63 out of 5 stars

3.5 Analyst's Opinion

Consensus Rating
Trilogy International Partners has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$3.00, Trilogy International Partners has a forecasted upside of 53.1% from its current price of C$1.96.
Amount of Analyst Coverage
Trilogy International Partners has only been the subject of 2 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Trilogy International Partners has received 215 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Trilogy International Partners has received 146 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Trilogy International Partners has received 59.56% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote “Outperform” if you believe TRL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Trilogy International Partners has a dividend yield of 1.43%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Trilogy International Partners does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trilogy International Partners insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$596,308.00 in company stock and sold C$0.00 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Trilogy International Partners is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trilogy International Partners is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Trilogy International Partners has a PEG Ratio of 34.56. PEG Ratios above 1 indicate that a company could be overvalued.

See Top Rated MarketRank™ Stocks Here

Trilogy International Partners (TSE:TRL) Frequently Asked Questions

Is Trilogy International Partners a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trilogy International Partners stock.
View analyst ratings for Trilogy International Partners or view top-rated stocks.

What stocks does MarketBeat like better than Trilogy International Partners?

Wall Street analysts have given Trilogy International Partners a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trilogy International Partners wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Trilogy International Partners' next earnings date?

Trilogy International Partners is scheduled to release its next quarterly earnings announcement on Monday, June 14th 2021.
View our earnings forecast for Trilogy International Partners.

How were Trilogy International Partners' earnings last quarter?

Trilogy International Partners Inc. (TSE:TRL) posted its quarterly earnings data on Wednesday, March, 24th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter. The specialty pharmaceutical company earned $220.01 million during the quarter.
View Trilogy International Partners' earnings history.

How has Trilogy International Partners' stock been impacted by COVID-19 (Coronavirus)?

Trilogy International Partners' stock was trading at C$1.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRL stock has increased by 3.2% and is now trading at C$1.96.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TRL?

2 equities research analysts have issued 12 month price objectives for Trilogy International Partners' shares. Their forecasts range from C$2.00 to C$4.50. On average, they anticipate Trilogy International Partners' stock price to reach C$3.00 in the next year. This suggests a possible upside of 53.1% from the stock's current price.
View analysts' price targets for Trilogy International Partners or view top-rated stocks among Wall Street analysts.

Who are Trilogy International Partners' key executives?

Trilogy International Partners' management team includes the following people:

Mr. John William Stanton B.A., M.B.A., BA, MBA, Co-Founder & Chairman (Age 66)
Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 65, Pay $788.78k)
Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 68)
Mr. Erik Mickels CPA, Sr. VP & CFO
Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.
Mr. Tomas Perez, Chief Exec. Officer of NuevaTel
Mr. Mark Aue, Chief Exec. Officer of 2degrees
Ms. Ann Saxton, VP of Investor Relations & Corp. Devel.
Mr. Juan Pablo Calvo, Pres of Nuevatel

Who are some of Trilogy International Partners' key competitors?

Some companies that are related to Trilogy International Partners include Beximco Pharmaceuticals (BXP), ECO Animal Health Group (EAH), Allergy Therapeutics (AGY), Sareum (SAR), Futura Medical (FUM), Avivagen (VIV), N4 Pharma (N4P), Cathay International Holdings Limited (CTI.L) (CTI), Antisense Therapeutics (ANP), Bayer Aktiengesellschaft (BAYN), Mayne Pharma Group (MAYNF), Mayne Pharma Group (MYX), Medical Developments International (MVP), Opthea (OPT) and Otsuka (OTSKY).
View all of TRL's competitors.

What other stocks do shareholders of Trilogy International Partners own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Emera (EMA), (MIICF), Merck & Co., Inc. (MRK), (ONCYF) (ONCYF), AxoGen (AXGN), A and W Revenue Royalties Income Fund (AW.UN), ATS Automation Tooling Systems (ATA), Algonquin Power & Utilities (AQN) and Apptio (APTI).

What is Trilogy International Partners' stock symbol?

Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."

How do I buy shares of Trilogy International Partners?

Shares of TRL and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Trilogy International Partners' stock price today?

One share of TRL stock can currently be purchased for approximately C$1.96.

How much money does Trilogy International Partners make?

Trilogy International Partners has a market capitalization of C$117.45 million and generates C$626.85 million in revenue each year.

How many employees does Trilogy International Partners have?

Trilogy International Partners employs 1,663 workers across the globe.

What is Trilogy International Partners' official website?

The official website for Trilogy International Partners is www.trilogy-international.co....

Where are Trilogy International Partners' headquarters?

Trilogy International Partners is headquartered at Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States.

How can I contact Trilogy International Partners?

Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here